No more NHI reimbursement limits on Zeffix

So far GSK's Zeffix, (lamivudine), a B virus hepatitis drug, has been under a restricted NHI reimbursement schedule, only for 2 year medication, but this restriction will be no longer applicable from 2006, indicating that the patient with B hepatitis will get benefits without any term limitation of NHI reimbursement.

According to Article 5, para. 2 of the NHI Payment Standards that was revis...